Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
City of Hope Medical Center
Duarte, California, United States
University of California San Diego Medical Center, Moores Cancer Center
La Jolla, California, United States
University of Michigan
Ann Arbor, Michigan, United States
The University of Nebraska Medical Center
Omaha, Nebraska, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Scri Oncology Partners
Nashville, Tennessee, United States
Vanderbilt Medical Center
Nashville, Tennessee, United States
Md Anderson Cancer Center
Houston, Texas, United States
Macquarie University Hospital
Sydney, New South Wales, Australia
Princess Alexandra Hospital Australia
Woolloongabba, Queensland, Australia
Start Date
January 8, 2026
Primary Completion Date
August 18, 2028
Completion Date
August 18, 2028
Last Updated
February 10, 2026
280
ESTIMATED participants
INCA036873
DRUG
Lead Sponsor
Incyte Corporation
NCT06898450
NCT06658951
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05101070